期刊文献+

苯甲酸阿格列汀有关物质的合成 被引量:1

Synthesis of Related Substances from Alogliptin Benzoate
下载PDF
导出
摘要 苯甲酸阿格列汀为二肽基肽酶抑制剂。为了对苯甲酸阿格列汀产品进行质量控制,以合成路线为基础,制备了4种有关物质,并且通过核磁共振和质谱确定了其化学结构。同时,根据有关物质的结构分析了其可能产生的原因。以此为基础,通过改善实验条件,成功合成出了符合质量标准的苯甲酸阿格列汀。 Alogliptin benzoate is one of the dipeptidyl peptidase inhibitors. To control the quality of the alogliptin benzoate, four re- lated substances were prepared based on the synthetic route,and the structures were confirmed by 1HNMR and MS. The reasons leading to the related substances were analysized based on the structures. The alogliptin benzoate that meet the quality standards successfully were synthesized via experimental condition improvement.
出处 《化学试剂》 CAS 北大核心 2015年第4期379-381,共3页 Chemical Reagents
关键词 苯甲酸阿格列汀 有关物质 合成 alogliptin benzoate related substances synthesis
  • 相关文献

参考文献11

  • 1安富荣,崔岚,王勤.治疗2型糖尿病新药二肽基肽酶-4抑制药阿格列汀[J].中国药师,2012,15(1):116-118. 被引量:15
  • 2赵兴旺,吴冰,赵临襄.阿格列汀(Alogliptin)[J].中国药物化学杂志,2013,23(4):337-337. 被引量:7
  • 3王珊,范鸣.抗2型糖尿病药物——Alogliptin[J].药学进展,2008,32(7):326-327. 被引量:7
  • 4徐佳骏,崔岚,沈金芳.治疗2型糖尿病的新药alogliptin[J].中国新药与临床杂志,2009,28(1):66-69. 被引量:6
  • 5TOMOKO A, YUSUKE M, OSAMU K. A novel dipeptidyl peptidase-4 inhibitor, alogliptin ( SYR-322 ) , is effective in diabetic rats with sulfonylurea-induced secondary fail- ure [ J ]. Life Sci. , 2009,85 ( 2 009 ) : 122-126. 被引量:1
  • 6PRATLEY R E. Alogliptin:a new,highly selective dipep- tidly peptidase-4 inhibitor for the treatment of type 2 dia- betes [ J ]. Expert Opin. Pharmacother. , 2009, 10 ( 3 ) : 503-512. 被引量:1
  • 7BULOTTA A, HUI H, ANASTASIE, et al. Cultured pan- creatic du ctal cells undergo cell cycle re-distribution and beta-cell like differentiation in response to glucogan-like pep tide-1 [ J ] J- Mol. Endocrionl. , 2002,29 ( 3 ) : 347- 360. 被引量:1
  • 8LITTLE T J, PILICHIEWICZ A N, RUSSO A, et al. Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses [ J ]. J. Clin. Endocrinol. Metab. , 2006,91 ( 5 ) : 1 916-1 923. 被引量:1
  • 9刘昭文,吴龙火,王恩军.苯甲酸阿格列汀的合成[J].海峡药学,2011,23(9):214-215. 被引量:18
  • 10崔翼,罗邻涛,周定康,等.一种苯甲酸阿格列汀的制备工艺:中国专利,201210510718.6[P].2012-12-04. 被引量:1

二级参考文献39

  • 1REUSCH JE,GADSBY R. Thiazolidinedione therapy: the benefits of aggressive and early use in type 2 diabetes [J]. Diabetes Technol Ther, 2003, 5(4): 685-693. 被引量:1
  • 2FENG J, ZHANG Z, WALLACE MB, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase 1V [J]. J Med Chem, 2007, 50 (10) : 2297-2300. 被引量:1
  • 3HOLST JJ,GROMADA J. Role of ineretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans[J]. Am J Physiol Endocrinol Metab, 2004, 287(2) : E199-E2061 被引量:1
  • 4DEACON CF. Therapeutic strategies based on glucagons-like peptide 1[J]. Diabetes, 2004, 53(5): 2181-2189. 被引量:1
  • 5NAUCK MA, MEIER JJ. Glucagon-like peptide 1 (GLP-1) and its derivatives in the treatment of diabetes[J]. Regul Pept, 2005, 128(2) : 135-148. 被引量:1
  • 6WRENGER S, FAUST J, MRESTANI-KLAUS C, et al. Nonsubstrate peptides influencing dipeptidyl peptidase Ⅳ/CD26 activity and immune cell function [J]. Front Biosci, 2008, 1 (13) : 3194-3201. 被引量:1
  • 7AHREN B, LANDIRR OM, JANSSON PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon level in type 2 diabetes[J]. J Clin Endocrinol Metab,2004, 89(5) : 2078-2084. 被引量:1
  • 8LEE B, SHI L, KASSEL DB, et al. Pharmaeokinetie and pharmacodynamic an efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys[J]. Eur J Pharmacol, 2008, 589(1-3): 306-314. 被引量:1
  • 9MORITOH Y, TAKEUCHI K, ASAKAWA T, et al. Chronic administration of alogliptin, a novel dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic oh/oh mice[J]. Eur J Pharmacol, 2008, 588 (2- 3) : 325-332. 被引量:1
  • 10CHRISTOPHER R, COVINGTON P, DAVENPORT M, et al. Pharmacokinetics, pbarmacodynamics, and tolerability of single increasing doses of the dipeptidyl pepti.dase-4 inhibitor alogliptin in healthy male subjects [J]. Clin Ther, 2008, 30(3) : 513-527. 被引量:1

共引文献36

同被引文献6

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部